Quattro Financial Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Quattro Financial Advisors LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 27,610.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,506 shares of the company’s stock after purchasing an additional 43,349 shares during the quarter. Johnson & Johnson accounts for 2.0% of Quattro Financial Advisors LLC’s investment portfolio, making the stock its 17th biggest position. Quattro Financial Advisors LLC’s holdings in Johnson & Johnson were worth $6,882,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Kennedy Capital Management LLC raised its holdings in Johnson & Johnson by 18.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock valued at $3,189,000 after buying an additional 3,206 shares during the last quarter. Rainsberger Wealth Advisors Inc. raised its stake in shares of Johnson & Johnson by 2.6% during the third quarter. Rainsberger Wealth Advisors Inc. now owns 14,584 shares of the company’s stock valued at $2,271,000 after acquiring an additional 373 shares during the last quarter. Industrial Alliance Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 125.4% during the third quarter. Industrial Alliance Investment Management Inc. now owns 6,671 shares of the company’s stock worth $1,039,000 after purchasing an additional 3,711 shares during the period. Annandale Capital LLC increased its holdings in Johnson & Johnson by 6.8% during the 3rd quarter. Annandale Capital LLC now owns 19,171 shares of the company’s stock valued at $2,986,000 after purchasing an additional 1,221 shares during the period. Finally, Dana Investment Advisors Inc. increased its holdings in Johnson & Johnson by 125.4% during the 3rd quarter. Dana Investment Advisors Inc. now owns 106,403 shares of the company’s stock valued at $16,572,000 after purchasing an additional 59,199 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on JNJ shares. The Goldman Sachs Group started coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Morgan Stanley cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Price Performance

JNJ stock opened at $145.62 on Thursday. The firm has a 50 day moving average price of $148.02 and a 200-day moving average price of $153.91. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm has a market capitalization of $350.46 billion, a price-to-earnings ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the business earned $2.68 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.